Australian-Singaporean regenerative medicine company Osteopore (ASX: OSX) has signed an Investment Agreement for strategic investment into a new entity (Regen SPV) to be setup by prominent and internationally recognised scientists Dr Xianmin Zeng and Dr Brian Kennedy.
Through the proposed strategic investment, Osteopore solidifies its commitment to advancing cutting-edge regenerative technologies that drive meaningful change while maintaining commercial viability.
As co-Founders of Regen SPV, Dr Zeng and Dr Kennedy will focus on integrating biotech and medtech to drive breakthroughs in tissue regeneration, disease cures, and the promotion of geroscience and longevity. Their work will continue to advance the broader understanding of aging and the application of regenerative medicine and cellular therapies to extend healthspan and combat age-related conditions.
Dr Xianmin Zeng is a leading expert in stem cell biology specialising in human embryonic stem cells and induced pluripotent stem cells (iPSC). Her research focuses on neural development using iPSC to model neurodegenerative diseases and bridges basic science and translational applications, making her a key figure in regenerative medicine and stem cell therapy.
Dr Zeng is the founder of USA-based RxCell Inc. – a leading iPSC company dedicated to advancing therapies that combat age-related degenerative diseases, including age-related macular degeneration (AMD). She achieved recognition from the California Institute for Regenerative Medicine (CIRM) for her research into stem cells during her tenure as Professor at the Buck Institute for Research on Aging.
Dr Brian Kennedy is a renowned expert in aging biology and is widely recognised for his work in translating aging research into strategies for improving longevity and preventing age- related diseases. His research focuses on the molecular mechanisms of aging and interventions that can extend health span, such as pharmaceuticals and lifestyle changes.
Dr Kennedy directs the Healthy Longevity Translational Research Programme at the National University of Singapore, where he is a distinguished Professor. He previously served as the President and CEO of the Buck Institute for Research on Aging, which is one
With OSX as a strategic investor, the Regen SPV will gain access to the Company’s clinical and technical advisory panel, leveraging OSX’s extensive expertise in research and development, clinical trials, regulatory processes, and commercialisation to accelerate the Regen SPV’s innovation and growth.
Osteopore Chairman, Mark Leong, said this move also solidifies the company’s leadership position in regenerative medicine.
“Our strategic investment with Dr Zeng and Dr Kennedy places us at the forefront of regenerative medicine. The synergies created positions Osteopore as a leader in scaffold based cellular therapy unlocking numerous exciting opportunities and applications across both regeneration and rejuvenation,” said Mr Leong.
